NCT06034197暂停早期 1 期
Pilot Open Label Study to Determine the Safety and Efficacy of Fluorescent Probe, VGT-309, to Identify Cancerous Colorectal Lesions During White-Light and Fluorescence Augmented Colonoscopy
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 暂停
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Safety Profile of VGT309
研究概览
简要总结
The purpose of this study is to determine the safety and feasibility of VGT-309 for the visualization of colorectal tumors in real-time using near-infrared (NIR) fluorescence endoscopy. In addition, signatures of 50+ biomarkers will be evaluated in biopsies using CODEX multi-plexing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with histologically confirmed distal colorectal adenocarcinoma of any stage.
- •Be willing and able to sign the informed consent and comply with study procedures.
- •Are scheduled to undergo a SOC colonoscopy for restaging following radiochemotherapy or are scheduled to receive a SOC colonoscopy in the OR prior to resection
- •Have acceptable kidney and liver functions at study entry as evidenced by:
- •ALT/AST < 1.5 times the upper limit of normal,
- •Creatinine clearance (according to Cockcroft-Gault Equation) > 50 mL/min
- •Total bilirubin < 1.5 times the upper limit of normal
- •Have an ECOG score of 0-
- •Be at least 18 years of age.
- •Female participants must be of non-childbearing potential, or, if of childbearing potential be non-pregnant or lactating and agree to use highly effective contraception from screening through 30 days after probe infusion
- •Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days post-dose and agree not to donate semen during this waiting period.
- •Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:
- •Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or
- •Intrauterine device or intrauterine hormone-releasing system. NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above. They are required to maintain abstinence from screening through Day 30, AND Participants in a same sex relationship, must use a barrier form of contraception (e.g., condom, diaphragm) to protect against the transfer of the study drug in any bodily fluids.
排除标准
- •Inclusion Criteria:
- •Adult patients with histologically confirmed distal colorectal adenocarcinoma of any stage.
- •Be willing and able to sign the informed consent and comply with study procedures.
- •Are scheduled to undergo a SOC colonoscopy for restaging following radiochemotherapy or are scheduled to receive a SOC colonoscopy in the OR prior to resection
- •Have acceptable kidney and liver functions at study entry as evidenced by:
- •ALT/AST < 1.5 times the upper limit of normal,
- •Creatinine clearance (according to Cockcroft-Gault Equation) > 50 mL/min
- •Total bilirubin < 1.5 times the upper limit of normal
- •Have an ECOG score of 0-
- •Be at least 18 years of age.
- •Female participants must be of non-childbearing potential, or, if of childbearing potential be non-pregnant or lactating and agree to use highly effective contraception from screening through 30 days after probe infusion
- •Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days post-dose and agree not to donate semen during this waiting period.
- •Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:
- •Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or
- •Intrauterine device or intrauterine hormone-releasing system. NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above. They are required to maintain abstinence from screening through Day 30, AND Participants in a same sex relationship, must use a barrier form of contraception (e.g., condom, diaphragm) to protect against the transfer of the study drug in any bodily fluids.
- •Exclusion Criteria:
- •Pregnant or breastfeeding females
- •They have a known allergy or reaction to ICG, other radiographic contrast agents, or any component of VGT-
- •Have congenital long QT syndrome or QTcF > 450ms (males) or >470ms (females) by history or at Screening ECG.
- •They are prisoners, institutionalized individuals, or are unable to consent for themselves.
- •Class 2 or higher obesity, defined by BMI ≥ 35.
- •Have any other comorbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.
研究组 & 干预措施
VGT-309
Experimental
Subjects will receive an IV infusion of 0.32 mg/kg VGT-309 12 to 36 hours before a standard of care endoscopy procedure.
干预措施: VGT-309 (Drug)
结局指标
主要结局
Safety Profile of VGT309
时间窗: 18 days
Safety profile will be measured by assessing number of Grade 2 or higher adverse events which have been determined to be clinically significant and definitely, probably or possibly related.
Feasibility of VGT-309
时间窗: 18 days
Feasibility to visualize colorectal tumors using NIR-endoscopy will be measured by the tumor-to-background ratio (fluorescence intensity of tumor tissue divided by the fluorescence intensity of normal surrounding tissue) and the concordance between white-light endoscopy assessment, histopathological examination and NIR imaging assessment.
次要结局
未报告次要终点
研究者
Stephan Rogalla
Clinical Assistant Professor, Medicine - Gastroenterology & Hepatology
Stanford University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase 2 Study of VGT-309 in Lung CancerLung CancerNCT05400226Vergent Bioscience, Inc.40
已完成
2 期
Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.Lung MetastasesLung CancerNCT06145048Vergent Bioscience, Inc.89
已完成
2 期
Nitric Oxide, GeNO Nitrosyl Delivery SystemPulmonary Arterial HypertensionNCT01165047Wake Forest University Health Sciences10
已完成
2 期
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in AdultsAtopic DermatitisPruritusNCT01232985Oculus Innovative Sciences, Inc.17
已完成
2 期
Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric OxidePulmonary Arterial HypertensionNCT01092559Geno LLC10